What is Androsta-3, 5-Diene-7, 17-Dione (ADT)?

ADT supplementation

Calm down!  I didn’t just pass out on the keyboard and start hitting some random keys!  Androsta-3, 5-Diene-7, 17-Dione is most definitely a real thing despite looking like something that came up as a result of mindless keyboard smashing.  For simplicity’s sake, we’re going to refer to it as ADT from here on out that way we can spend more time processing the useful information than we can trying to learn how to pronounce this potent supplement.

ADT isn’t something that’s universally studied or used.  That’s not to say there are no studies available to review at all [1].  Being sort of short on reported information is usually something we at Vaxxen discourage.  In this particular scenario, we’ve seen the benefits first hand so we are going to insist that you take ADT supplementation in to consideration.  Let’s take a deep dive together…

Aromatase Inhibitor

ADT is classified as an irreversible aromatase inhibitor, meaning it’s an extra strong class of drug that it usually used to treat older men and women for cancer.  Postmenopausal women are often prescribed these aromatase inhibitors to help prevent the spread of breast cancer while men can use it to treat unusually enlarged breasts [2].  Yes, man boobs are a real thing and it’s called gynecomastia.  While it’s not life threatening, gynecomastia is an embarrassing ailment that tends to shows up in close to 70% of adolescent boys and lasts for a couple of years.  Unfortunately, it can be life long.

As for ADT, it can be used to convert androgens to estrogen.  Some of the ADT supplementation that takes place is to ease the pain of life long gynecomastia.  Some of the ADT supplementation that takes place is to treat breast cancer.  What we care about is the ADT supplementation that takes place to help revert hormonal levels back to normal through aromatase inhibition after extreme cycles of supplementation!

Post Cycle Support

ADT is an up and coming form of post cycle support that has been proven to help bring hormonal levels in both men and women back to normal levels [3].  As you know, when you use powerful testosterone supplements, you can throw your body out of whack and cause permanent damage if you don’t take measures to treat the side effects.  ADT is used in the best post cycle therapy products out on the market.  At Vaxxen, we’ve included a modest dose in our Descend product to help you return your system to its pre-cycle, optimal operational level.  Rebalancing is absolutely essential and should not go overlooked when you’re done using even the gentlest of hormone altering supplements.  As listed on our website, ADT has the ability to:

  • Create a strong bond with aromatase enzyme
  • Offer the benefits of aromasin without the expense and need for a prescription
  • Reduce cortisol, which your body releases when under stress
  • Encourage weight loss
  • Boost the immune system in clinical studies
  • Improve conditions related to aging

Note: If you’re going to look around for alternatives to Descend or for straight up ADT supplementation, be aware that it also goes by the nickname Androsta.  Good luck!

References

  1. Numazawa M1, Mutsumi A, Tachibana M, Hoshi K.
    Synthesis of androst-5-en-7-ones and androsta-3,5-dien-7-ones and their related 7-deoxy analogs as conformational and catalytic probes for the active site of aromatase
    J Med Chem. 1994 Jul 8;37(14):2198-205.
  2. Reva Schneider,1 Ayman Barakat,1 John Pippen,1,2,3 and Cynthia Osborne1,2,3
    Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
    Breast Cancer (Dove Med Press). 2011; 3: 113–125.
    Published online 2011 Oct 4. doi: 10.2147/BCTT.S22905
  3. Hendrik Isbarn,a,* Laurent Boccon-Gibod,b Peter R. Carroll,c Francesco Montorsi,d Claude Schulman,e Matthew R. Smith,f Cora N. Sternberg,g and Urs E. Studerh
    Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
    Eur Urol. Author manuscript; available in PMC 2011 May 10.
    Published in final edited form as:
    Eur Urol. 2009 Jan; 55(1): 62–75.
    Published online 2008 Oct 14. doi: 10.1016/j.eururo.2008.10.008
Leave a Reply

Your email address will not be published. Required fields are marked *